Expansion of key cell subsets; namely, CD20⁺B cells, CD8⁺CD11b⁻T cells, and CD16⁺CD57⁻NK cells, significantly positively affected 2-year OS. There were no significant differences in CIR or proportions of high vs low cell counts for CD20⁺ B cell and CD8⁺CD11b- T cell subsets. NRM benefits were found to be lower (range, 17%-21%) in patients with early IR of these cells. CIR was confirmed to be approximately 26% lower in patients with early IR of CD16⁺CD57⁻ NK cells.